154 related articles for article (PubMed ID: 28249268)
21. Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide.
Dekker SEI; Bierau J; Giera M; Blomberg N; Drenth JPH; Mayboroda OA; de Fijter JW; Soonawala D;
Eur J Clin Invest; 2024 Apr; 54(4):e14147. PubMed ID: 38071418
[TBL] [Abstract][Full Text] [Related]
22. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases.
Fabris L; Cadamuro M; Fiorotto R; Roskams T; Spirlì C; Melero S; Sonzogni A; Joplin RE; Okolicsanyi L; Strazzabosco M
Hepatology; 2006 May; 43(5):1001-12. PubMed ID: 16628643
[TBL] [Abstract][Full Text] [Related]
23. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management.
Cnossen WR; Drenth JP
Orphanet J Rare Dis; 2014 May; 9():69. PubMed ID: 24886261
[TBL] [Abstract][Full Text] [Related]
24. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
[TBL] [Abstract][Full Text] [Related]
25. Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease.
Onori P; Mancinelli R; Franchitto A; Carpino G; Renzi A; Brozzetti S; Venter J; Francis H; Glaser S; Jefferson DM; Alpini G; Gaudio E
Liver Int; 2013 Jul; 33(6):914-25. PubMed ID: 23617956
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib.
Sato Y; Harada K; Furubo S; Kizawa K; Sanzen T; Yasoshima M; Ozaki S; Isse K; Sasaki M; Nakanuma Y
Am J Pathol; 2006 Oct; 169(4):1238-50. PubMed ID: 17003482
[TBL] [Abstract][Full Text] [Related]
27. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.
Gradilone SA; Masyuk TV; Huang BQ; Banales JM; Lehmann GL; Radtke BN; Stroope A; Masyuk AI; Splinter PL; LaRusso NF
Gastroenterology; 2010 Jul; 139(1):304-14.e2. PubMed ID: 20399209
[TBL] [Abstract][Full Text] [Related]
28. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
[TBL] [Abstract][Full Text] [Related]
29. Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion.
Fiorotto R; Spirlì C; Fabris L; Cadamuro M; Okolicsanyi L; Strazzabosco M
Gastroenterology; 2007 Nov; 133(5):1603-13. PubMed ID: 17983806
[TBL] [Abstract][Full Text] [Related]
30. TGR5 in the Cholangiociliopathies.
Masyuk TV; Masyuk AI; LaRusso NF
Dig Dis; 2015; 33(3):420-5. PubMed ID: 26045278
[TBL] [Abstract][Full Text] [Related]
31. Genetics, pathobiology and therapeutic opportunities of polycystic liver disease.
Olaizola P; Rodrigues PM; Caballero-Camino FJ; Izquierdo-Sanchez L; Aspichueta P; Bujanda L; Larusso NF; Drenth JPH; Perugorria MJ; Banales JM
Nat Rev Gastroenterol Hepatol; 2022 Sep; 19(9):585-604. PubMed ID: 35562534
[TBL] [Abstract][Full Text] [Related]
32. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha.
Alpini G; Baiocchi L; Glaser S; Ueno Y; Marzioni M; Francis H; Phinizy JL; Angelico M; Lesage G
Hepatology; 2002 May; 35(5):1041-52. PubMed ID: 11981754
[TBL] [Abstract][Full Text] [Related]
33. Insignificant effect of secretin in rodent models of polycystic kidney and liver disease.
Wang X; Ye H; Ward CJ; Chu JY; Masyuk TV; Larusso NF; Harris PC; Chow BK; Torres VE
Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1089-98. PubMed ID: 22811488
[TBL] [Abstract][Full Text] [Related]
34. Structural and functional analyses of liver cysts from the BALB/c-cpk mouse model of polycystic kidney disease.
Muchatuta MN; Gattone VH; Witzmann FA; Blazer-Yost BL
Exp Biol Med (Maywood); 2009 Jan; 234(1):17-27. PubMed ID: 18997107
[TBL] [Abstract][Full Text] [Related]
35. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
Banales JM; Masyuk TV; Bogert PS; Huang BQ; Gradilone SA; Lee SO; Stroope AJ; Masyuk AI; Medina JF; LaRusso NF
Am J Pathol; 2008 Dec; 173(6):1637-46. PubMed ID: 18988797
[TBL] [Abstract][Full Text] [Related]
36. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
Holditch SJ; Schreiber CA; Harris PC; LaRusso NF; Ramirez-Alvarado M; Cataliotti A; Torres VE; Ikeda Y
Kidney Int; 2017 Sep; 92(3):657-668. PubMed ID: 28416225
[TBL] [Abstract][Full Text] [Related]
37. Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease.
Brock WJ; Beaudoin JJ; Slizgi JR; Su M; Jia W; Roth SE; Brouwer KLR
Int J Toxicol; 2018; 37(2):144-154. PubMed ID: 29587557
[TBL] [Abstract][Full Text] [Related]
38. Feeding soy protein isolate and n-3 PUFA affects polycystic liver disease progression in a PCK rat model of autosomal polycystic kidney disease.
Maditz KH; Benedito VA; Oldaker C; Nanda N; Lateef SS; Livengood R; Tou JC
J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):467-73. PubMed ID: 25822773
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of Aquaporin 1 on cysts of patients with polycystic liver disease.
Li D; Shi X; Zhao L; Liang Z; Xie S; Wang G
Rev Esp Enferm Dig; 2016 Feb; 108(2):71-8. PubMed ID: 26838488
[TBL] [Abstract][Full Text] [Related]
40. New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease.
Barten TRM; Bernts LHP; Drenth JPH; Gevers TJG
Expert Opin Ther Targets; 2020 Jun; 24(6):589-599. PubMed ID: 32250187
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
